- Home
- PODC vs TENX Comparison
PODC vs TENX Comparison
Compare PODC & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PODC | TENX |
|---|---|---|
| Founded | 2013 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.5M | 56.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PODC | TENX |
|---|---|---|
| Price | $2.67 | $12.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $22.50 |
| AVG Volume (30 Days) | 129.4K | ★ 320.5K |
| Earning Date | 02-06-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $56,957,000.00 | N/A |
| Revenue This Year | $17.27 | N/A |
| Revenue Next Year | $19.90 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 20.01 | N/A |
| 52 Week Low | $1.28 | $4.63 |
| 52 Week High | $3.21 | $18.38 |
Technical Indicators
Market Signals| Indicator | PODC | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 52.53 | 44.14 |
| Support Level | $2.57 | $12.40 |
| Resistance Level | $3.21 | $13.37 |
| Average True Range (ATR) | 0.30 | 1.10 |
| MACD | -0.00 | -0.44 |
| Stochastic Oscillator | 37.29 | 5.87 |
Price Performance
Historical ComparisonAbout PODC PodcastOne Inc.
PodcastOne Inc is a podcast platform and publisher that makes its content available to audiences via all podcasting distribution platforms, including its website, its PodcastOne app, Apple Podcasts, Spotify, Amazon Music, and more.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.